Search Within

Tiffany A Traina

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (49)
  2. Journal Article (34)
  3. Guidelines (1)
  4. Review (1)
Groups
  1. Biostatistics Service (85)
  2. Breast Medicine Service (85)
  3. Department of Medicine (85)
  4. Epidemiology and Biostatistics (85)
  5. Solid Tumor Oncology Division (85)
  6. Survivorship Research (85)

More Groups

People
  1. Sujata Patil (62)
  2. Clifford Hudis (47)
  3. Larry Norton (33)
  4. Ayca Gucalp (24)
  5. Chau Dang (20)
  6. Mark Robson (20)

More People

Years
  1. 2024 (5)
  2. 2023 (3)
  3. 2022 (5)
  4. 2021 (4)
  5. 2020 (4)
  6. 2019 (2)

More Years

Publications
  1. Journal of Clinical Oncology (25)
  2. Cancer Research (15)
  3. Breast Cancer Research and Treatment (7)
  4. Clinical Cancer Research (4)
  5. International Journal of Radiation Oncology, Biology, Physics (4)
  6. Annals of Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (25)
  2. American Association for Cancer Research (19)
  3. Springer (13)
  4. Elsevier Inc. (10)
  5. Oxford University Press (4)
  6. John Wiley & Sons (3)

More Publishers

Results (85)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer
    Meeting Abstract

    Mcarthur, H. L.; Rugo, H.; Paulson, M.; Rourke, M.; Traina, T.; Panageas, K.; Steingart, R.; Dang, C.; Fornier, M.; Park, J.; more...
    Breast Cancer Research and Treatment (2007)

    Fulltext@MSK | Save
  • Optimizing chemotherapy administration: A phase I study of biweekly capecitabine dose and schedule based on Norton-Simon mathematical modeling
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Dugan, U.; Feigin, K.; Panageas, K.; Hodgman, E.; Norton, L.; Hudis, C. A.
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Traina, T. A.; Rugo, H.; Caravelli, J.; Yeh, B.; Panageas, K.; Bruckner, J.; Norton, L.; Park, J.; Hudis, C.; Dickler, M.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • A phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer
    Meeting Abstract

    Traina, T. A.; Dickler, M. N.; Caravelli, J. F.; Yeh, B. M.; Brogi, E.; Panageas, K.; Flores, S. A.; Norton, L.; Park, J.; Hudis, C.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • A feasibility study of an aromatase inhibitor (Al), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizurnab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Traina, T. A.; Dickler, M. N.; Caravelli, J. F.; Yeh, B. M.; Brogi, E.; Panageas, K.; Flores, S. A.; Norton, L.; Hudis, C.; Rugo, H.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save